Photo: Jacquelyn Martin/POOL/AFP via Getty Images The Food and Drug Administration authorized the Pfizer-BioNTech coronavirus vaccine for emergency use in children ages 5 to 11 on Friday. This comes after an independent advisory panel for the agency approved a lower dose of the Pfizer shot for kids on Tuesday. As a result, coronavirus vaccines should be available for 28 million children in the United States as early as next week.
The FDA authorized a regiment of two 10-milligram doses, smaller than the standard 30-milligram dose received by those 12 years and older, which will be administered three weeks apart. With the agency’s final authorization, the next step in the regulatory process is a sign off from an advisory panel at the Centers for Disease Control and Prevention, which meets on Tuesday, followed by the final endorsement from CDC director Dr. Rochelle Walensky. At that point, vaccines for kids over the age of 5 could begin, pending the approval of the highest authority: parents.
According to FDA data given to the Vaccines and Related Biological Products Advisory Committee on Tuesday, children ages 5 to 11 make up around 9 percent of all coronavirus cases in the United States; in the past six weeks, the number of confirmed COVID cases in children has shot up by over 1.1 million. Panel members also suggested that providing shots for kids could push the country toward an “endemic” phase, wherein the virus exists among others as a largely seasonal, much less fatal disease.
veramagalhaes Pode traduzir? 99% da população fala apenas português!
veramagalhaes E, por aqui, o imbecil do presidente e seus filhos não querem a vacinação de crianças, estimulando malucos a ameaçarem de morte os diretores da Anvisa.
Moloch approves! NoVaccineMandates
veramagalhaes Fantastic
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ScaryMommy - 🏆 116. / 63 Read more »
Source: Forbes - 🏆 394. / 53 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: Newsweek - 🏆 468. / 52 Read more »
Source: WebMD - 🏆 709. / 51 Read more »